New Share Alert | Okada Pharma Files for Hong Kong Listing

Stock News

Jan 27

It was disclosed by the Hong Kong Stock Exchange on January 26 that Shanghai Okada Pharmaceutical Technology Co., Ltd. (Okada Pharma) has submitted a listing application for the Main Board of the Hong Kong Stock Exchange, with CMBI and CCB International acting as its joint sponsors. According to the prospectus, Okada Pharma possesses its self-developed innovative drug delivery platform, has established an integrated internal system covering R&D, production, sales, and marketing, and has built a rich global product pipeline. The company adopts the 505(b)(2) regulatory pathway, focusing on specific therapeutic areas, and leverages its self-constructed full-system capabilities in R&D, production, and commercialization to achieve operational synergies.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1151443681"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1151443681\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1151443681?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-27 08:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1151443681","market":"us","top_or_hot":-1,"title":"New Share Alert | Okada Pharma Files for Hong Kong Listing","media":"Stock News","content":"<p>It was disclosed by the Hong Kong Stock Exchange on January 26 that Shanghai Okada Pharmaceutical Technology Co., Ltd. (Okada Pharma) has submitted a listing application for the Main Board of the Hong Kong Stock Exchange, with CMBI and CCB International acting as its joint sponsors.\nAccording to the prospectus, Okada Pharma possesses its self-developed innovative drug delivery platform, has established an integrated internal system covering R&D, production, sales, and marketing, and has built a rich global product pipeline.\nThe company adopts the 505(b)(2) regulatory pathway, focusing on specific therapeutic areas, and leverages its self-constructed full-system capabilities in R&D, production, and commercialization to achieve operational synergies.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>New Share Alert | Okada Pharma Files for Hong Kong Listing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNew Share Alert | Okada Pharma Files for Hong Kong Listing\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-27 08:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>It was disclosed by the Hong Kong Stock Exchange on January 26 that Shanghai Okada Pharmaceutical Technology Co., Ltd. (Okada Pharma) has submitted a listing application for the Main Board of the Hong Kong Stock Exchange, with CMBI and CCB International acting as its joint sponsors.\nAccording to the prospectus, Okada Pharma possesses its self-developed innovative drug delivery platform, has established an integrated internal system covering R&D, production, sales, and marketing, and has built a rich global product pipeline.\nThe company adopts the 505(b)(2) regulatory pathway, focusing on specific therapeutic areas, and leverages its self-constructed full-system capabilities in R&D, production, and commercialization to achieve operational synergies.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09939","symbol_name":"开拓药业-B","start_time":0,"source_url":"","article_id":"1151443681","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1151443681","pubTimestamp":1769472858,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"It was disclosed by the Hong Kong Stock Exchange on January 26 that Shanghai Okada Pharmaceutical Technology Co., Ltd. (Okada Pharma) has submitted a listing application for the Main Board of the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","09939":"开拓药业-B","BK1574":"生物医药B类股","AUDC":"奥科","BK4020":"通信设备","BK1515":"抗疫概念","BK1161":"生物科技"},"translate_title":"新股快讯|冈田制药申请香港上市","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"09939":1,"HEXmain":1,"AUDC":1},"content_text":"It was disclosed by the Hong Kong Stock Exchange on January 26 that Shanghai Okada Pharmaceutical Technology Co., Ltd. (Okada Pharma) has submitted a listing application for the Main Board of the Hong Kong Stock Exchange, with CMBI and CCB International acting as its joint sponsors.\nAccording to the prospectus, Okada Pharma possesses its self-developed innovative drug delivery platform, has established an integrated internal system covering R&D, production, sales, and marketing, and has built a rich global product pipeline.\nThe company adopts the 505(b)(2) regulatory pathway, focusing on specific therapeutic areas, and leverages its self-constructed full-system capabilities in R&D, production, and commercialization to achieve operational synergies.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}